Board summary
Key figures
57,149
Registered population
60.3% aged 18–64
18.8%
Aged 65+
ICB 14.9% · England 17.9%
21.2%
In IMD quintile 1
ICB 40.7% · England 21.0%
~17,364
Core20 residents (est.)
Resident basis; registered basis ~12,148 · see page 3
9,377
Hypertension register
+8.42% in 3 yrs · England +5.60%
518
SMI register
14.5% of Wigan (LAD)'s
1,423
COPD register
Reviews -0.70% in 3 yrs
Forecast to 2030
11,487
Hypertension patients, 2030
+2,110 on today
78.5%
QRISK ≥20% on statins, 2030
+5.76pp over 3 yrs
4.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Pre-school MMR second dose and booster drop-off.
Age-five MMR coverage drops 10.2 pp from dose 1 (97.2%) to dose 2 (87.0%), matching 4-in-1 boosters (87.0%, 8 pp below the 95.0% target).
Heart failure reviews falling behind England.
Heart failure annual reviews fell 11.4% over 2023 to 2025 (England +8.7%) to 71.0% (England 78.5%), while asthma leaves a 1,448-patient unreviewed scale.
Population, age and ethnicity
TABA WIGAN PCN serves 57,149 patients with 18.8% aged 65 and over
TABA WIGAN PCN serves 57,149 registered patients. Patients aged 65 and over comprise 18.8% (10,740 patients), in line with Wigan (LAD) at 18.8%, and above NHS Greater Manchester Integrated Care Board (14.9%) and England (17.9%). Children aged 0-17 represent 20.9% (11,924 patients), compared with 20.0% in Wigan (LAD), 21.8% in the ICB and 19.6% in England. Gypsy or Irish Traveller and Roma residents each represent 0.1% of usual residents. Projected list growth to 2030 is 2.0% (Wigan 1.1%, ICB 1.6%, England 2.3%) under unverified methods. Registered counts lack supplied observation periods.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Wigan (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Wigan LA) | 2,706 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 86.6% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 63.1% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Wigan LA) | 1,243 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Wigan LA) | 12.3 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation matches England overall but spans 41.0 percentage points across practices
The PCN Core20 share is 21.2%, below Wigan (29.4%) and NHS Greater Manchester ICB (40.7%), and in line with England (21.0%). Across practices, shares span a 41.0 pp range: Poplar Street Surgery records 41.0% (2,343 estimated patients), while Sivakumar & Partner, Boothstown Medical Centre, and Dr Vardhan's Surgery each record 0.0%. Dr Kk Chan & Partners has the largest volume at 2,940 estimated patients (33.2%). Practice estimates sum to 12,148 registered patients versus 17,364 resident decile 1 and 2 individuals, so outreach must balance concentration against volume.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
518
SMI register
0.91% recorded prevalence
346
Learning disability register
0.61% recorded prevalence
11
Care homes, 327 beds
In the PCN catchment
10.1%
Provide unpaid care
Wigan (LAD), Census 2021
The PCN records 518 SMI patients (0.9% vs Wigan 1.0%, ICB 1.1%, England 1.0%) and 346 learning disability patients (0.6% vs Wigan 0.7%, ICB 0.6%, England 0.6%). Catchment care homes comprise 327 beds across 11 sites. Borough figures record 11 rough sleepers (2025) and 10.1% unpaid care, not extrapolatable to PCN lists.
Severe mental illness: physical health checks
SMI prevalence is 0.9% (518 patients). Recorded checks reached 87.7% for blood pressure (England 83.4%), 89.5% for BMI (England 82.1%), and 87.0% for alcohol (England 81.8%). Uncaptured check elements mean full physical check completion cannot be confirmed.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
9,377
Hypertension register
+8.42%
Register growth, 3 yrs
Wigan (LAD) +10.59% · England +5.60%
+3.86pp
BP control, under 80
≤140/90 · +6.51pp aged 80+
+2,110
More patients by 2030
Forecast 11,487 (19.39%)
Hypertension case-finding and control
Recorded hypertension prevalence is 16.5% (9,377 patients), which sits above England (15.2%) and NHS Greater Manchester ICB (14.4%), but trails Wigan (LAD) at 18.0%. Crude register modelling indicates a scenario gap of 934 patients against the borough benchmark, though this is not age-adjusted and does not confirm undiagnosed disease. Blood pressure checks reach 91.2% (England 90.0%), and 76.5% are treated to target, exceeding Wigan (75.6%), the ICB (71.4%) and England (70.3%). Trailing borough prevalence may reflect age structure or case-finding differences, testable by practice audit.
Lipids and statins
Among diabetic patients without cardiovascular disease, statin coverage is 70.2%, trailing Wigan (72.5%), England (73.2%) and NHS Greater Manchester ICB (75.7%). Therapy for QRISK ≥ 20% reaches 65.2% (England 63.6%). Lower primary prevention statin coverage highlights an opportunity to review prescribing for at-risk diabetic patients.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 98,709 | £2.20 | £1.94 | £1.86 | £217,160 |
| Cardiovascular (all), 2025 | 131,864 | £3.79 | £3.15 | £3.33 | £499,765 |
In 2026, the PCN prescribed 98,709 lipid-modifying items at £2.20 per item, compared with £2.09 in Wigan (LAD), £1.94 in NHS Greater Manchester ICB and £1.86 in England. This represents £33,561 more than at England's unit cost. Higher unit costs indicate an opportunity to review prescribing choices to align with ICB and national benchmarks.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+1.22%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+4.78%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 8.1% (4,313 patients; England 6.6%), with prescribing of 2,478 items per 1,000 aged 5-19 (England 1,488). Annual reviews reached 66.4% (England 65.7%), leaving a scale of 1,448 unreviewed patients. COPD prevalence is 2.5% (1,423 patients; Wigan 2.6%), but the register fell 0.6% over 2023 to 2025 while Wigan (LAD) grew +6.2% and England +2.6%. While COPD reviews reached 79.8% (England 76.4%), the contracting register could reflect diagnostic or case-finding differences, testable by practice audit.
Cancer register and children's immunisation
The cancer register grew +11.5% over 2023 to 2025 to 2,258 patients (4.0% prevalence; England 3.8%). In Q1 2025/26, age-5 MMR dose 1 reaches 97.2% (England 91.7%), but dose 2 drops 10.2 pp to 87.0%, matching the 4-in-1 booster at 87.0% (both 8 pp below the 95.0% target across 177 children). This drop-off could reflect recall timing gaps, testable by checking practice reminder logs.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, NHS Greater Manchester ICB recorded 55.6% of staged cancers diagnosed at stage 1 or 2 (6,491 of 11,679 known-stage cases; England 55.3%), sitting 19.4 pp below the 75.0% national ambition by 2028. Known stage was recorded for 70.8% of 16,492 registered cancers (England 67.0%). Early-stage share rose +3.1 pp from 52.4% in 2013, leaving an ICB scale gap of about 2,270 extra early diagnoses annually. System staging reflects regional diagnostics, not PCN performance. In TABA WIGAN PCN, cervical screening reached 75.2% (England 66.8%), though screening reached 66.2% at Elliott Street Surgery and 66.3% at The Surgery, Tyldesley.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Bolton NHS Foundation Trust, 69.66% of patients met the 62-day referral to treatment standard, sitting 15.3 pp below the 85.0% standard. For the 28-day faster diagnosis standard, Bolton achieved 80.48% (distance 5.5 pp to the 75.0% standard) and met the 31-day combined standard at 96.50% (standard 96.0%, distance 0.5 pp). Across NHS Greater Manchester ICB, the 62-day standard reached 75.73% (sitting 9.3 pp below the 85.0% standard), while 28-day faster diagnosis achieved 79.53% (distance 4.5 pp) and the 31-day standard was 96.49% (distance 0.5 pp).
| Pathways within standard (%) | Bolton | Manchester | Northern Care Alliance | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.48 | 80.06 | 75.20 | 79.53 | 79.32 |
| 31-day treatment (96%) | 96.50 | 92.54 | 94.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 69.66 | 72.85 | 78.65 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Bolton | Manchester | Northern Care Alliance | England |
|---|---|---|---|---|
| MRI | 2.05 | 11.68 | 5.09 | 21.40 |
| CT | 19.40 | 14.66 | 4.10 | 9.92 |
| Echocardiography | 3.48 | 4.91 | 31.48 | 28.48 |
| Colonoscopy | 1.33 | 4.51 | 40.04 | 30.83 |
| Gastroscopy | 2.06 | 29.35 | 36.48 | 29.02 |
| All 15 DM01 tests | 15.78 | 8.98 | 15.71 | 23.14 |
| Community services activity | Wigan residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 48,150 | 573,310 |
| Referrals | 13,750 | 94,470 |
| Patients with a contact | 18,695 | 183,535 |
Community services (residents of Wigan), Jun 2026 (provisional). In the Community Services Dataset for June 2026 (provisional), adults aged 65 and over accounted for 58.5% of community service contacts among borough residents, representing 28,190 of 48,150 total contacts. Activity is reported at local authority level rather than PCN or provider level.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, QOF vaccination and immunisation domain achievement spanned 41.7 pp across practices, from 43.8% at Dr Vasanth to 85.5% at Bee Fold Medical Centre (England 55.2%). In contrast, clinical-domain achievement reached 96.9% to 100.0%. This variation could reflect practice-level call-recall and access differences, though this has not been confirmed locally.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Meadowview Surgery | 106 | 32.9 | 89.0% | 76.2% | 91.6% |
| Sivakumar & | 127 | 0.0 | 87.6% | 78.9% | 89.4% |
| Astley General | 88 | 3.0 | 73.4% | 88.1% | 88.5% |
| Elliott Street | 104 | 24.9 | 76.1% | 82.6% | 86.1% |
| Poplar Street | 106 | 41.0 | 77.3% | 82.3% | 86.0% |
| Dr Kk Chan & | 110 | 33.2 | 66.4% | 72.8% | 85.1% |
| Dr Vardhan's | 108 | 0.0 | 81.8% | 74.1% | 82.5% |
| Bee Fold | 108 | 31.6 | 84.4% | 80.2% | 80.9% |
| Tyldesley | 108 | 31.4 | 75.2% | 77.4% | 78.4% |
| Dr Vasanth | 83 | 38.7 | 68.8% | 63.6% | 73.7% |
| Boothstown | 98 | 0.0 | 45.3% | 65.0% | 68.3% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eight trends trail England, led by heart failure reviews, alongside strong diabetes control
Eight measures trail England over three years. Heart failure reviews fell 11.4% (England +8.7%), leaving current achievement at 71.0% (England 78.5%). Stroke register prevalence fell 1.3% (England +2.3%), and smoking cessation offers declined 2.3 pp (England +0.1 pp). Conversely, non-frail diabetes HbA1c control rose 18.9% (England +4.4%) to 63.1% (England 57.4%), and dementia register prevalence grew 16.2% (England +6.0%). Slower review and register growth may reflect selective recall timing rather than lower underlying need, though this remains unverified locally.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Learning disability register
Stroke register
COPD reviews
COPD register
Diabetes HbA1c control
BP control, 80+
BMI record (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Wigan (LAD) | Asset | PCN | Wigan (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 11 (327 beds) | n/a | Schools (catchment) | 69 | n/a |
| Children's centres | 4 | 20 | Places of worship | 29 | 164 |
| Libraries | 2 | 10 | Primary schools (LA maintained) | 17 | 68 |
| Primary academies | 3 | 21 | Special schools | n/a | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Pre-school MMR2 and booster recall
In Q1 2025/26 across 177 children aged 5, MMR dose 2 and the 4-in-1 booster both reached 87.0%, 10.2 pp below MMR dose 1 (97.2%). For discussion, practices could audit age-five call-recall lists, synchronise MMR2 and 4-in-1 invitations, and offer flexible pre-school clinic slots. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 2
Asthma annual review and prescribing recall
Asthma prevalence is 8.1% (4,313 patients; England 6.6%) with 66.4% reviewed in 12 months (England 65.7%), leaving a scale of 1,448 unreviewed patients. For discussion, the PCN could run a single-template asthma recall combining annual review with inhaler checks, prioritising Core20 practices. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Targeted hypertension case-finding audit
Recorded hypertension prevalence is 16.5% (9,377 patients), above England (15.2%, -673 scenario) but below Wigan (18.0%), a crude gap of up to 934 patients. For discussion, practices could search records for repeated raised BP readings without a hypertension code and offer opportunistic checks in Core20 practices. Low cost, quick to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Differentiated Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Targeted hypertension case finding (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Pre-school MMR2 and booster recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 2 · Asthma annual review and prescribing recall (p12) | Asthma register · Asthma: QOF prevalence · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 3 · Targeted hypertension case-finding audit (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
